Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: A population-based cohort study.
鈉-葡萄糖共轉運蛋白-2 抑制劑與肥厚型心肌病及糖尿病患者的臨床結果:一項基於人群的隊列研究。
Eur J Prev Cardiol 2024-11-22
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.
腸道微生物群、胰高血糖素樣肽受體激動劑與營養的相互作用:代謝功能障礙相關脂肪肝疾病治療的新前沿。
World J Gastroenterol 2024-11-22
Comparing the Accuracy and Readability of Glaucoma-related Question Responses and Educational Materials by Google and ChatGPT.
比較 Google 和 ChatGPT 在青光眼相關問題回答及教育材料的準確性和可讀性。
J Curr Glaucoma Pract 2024-11-22
Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders.
近年來在管理2型糖尿病及相關代謝疾病中,胰高血糖素樣肽-1 (GLP-1) 激動劑的最新進展與治療益處。
Cureus 2024-11-22
Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis.
美國 GLP-1 受體激動劑處方中的種族和族裔差異:一項回顧性隊列分析。
medRxiv 2024-11-22
The Emboless® venous chamber efficiently reduces air bubbles: a randomized study of chronic hemodialysis patients.
Emboless® 靜脈腔有效減少氣泡:一項針對慢性血液透析患者的隨機研究。
Clin Kidney J 2024-11-22
Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis.
慢性腎病患者(有或無第二型糖尿病)中鈉-葡萄糖共轉運蛋白-2抑制劑的系統評價與統合分析。
BMJ Med 2024-11-22
The performance of ChatGPT in day surgery and pre-anesthesia risk assessment: a case-control study of 150 simulated patient presentations.
ChatGPT 在日間手術和麻醉前風險評估中的表現:150 例模擬病人案例對照研究。
Perioper Med (Lond) 2024-11-22